NTLA — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

35.19

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

-0.07

EPS Last/This Y

0.25

EPS This/Next Y

0.63

Price

13.56

Target Price

25.2

Analyst Recom

2.08

Performance Q

44.61

Upside

-1,089.3%

Beta

2.04

Ticker: NTLA

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	NTLA	13.88	0.32	0.08	105215
2026-03-10	NTLA	13.47	0.32	0.19	104870
2026-03-11	NTLA	13	0.32	1.13	105003
2026-03-12	NTLA	12.85	0.31	0.24	105040
2026-03-13	NTLA	12.85	0.31	0.24	105040
2026-03-17	NTLA	13.5	0.30	0.06	105617
2026-03-18	NTLA	13.21	0.30	0.09	106054
2026-03-19	NTLA	13.14	0.30	0.51	106181
2026-03-20	NTLA	12.86	0.30	0.07	105944
2026-03-23	NTLA	13.1	0.26	0.23	97507
2026-03-24	NTLA	12.83	0.27	0.79	98314
2026-03-25	NTLA	13.27	0.26	0.05	98155
2026-03-26	NTLA	13.26	0.26	0.12	98153
2026-03-27	NTLA	12.37	0.26	2.65	98767
2026-03-30	NTLA	11.65	0.28	1.11	100222
2026-03-31	NTLA	12.81	0.28	0.21	100752
2026-04-01	NTLA	13.27	0.28	0.56	101118
2026-04-02	NTLA	13.12	0.28	0.38	101285
2026-04-06	NTLA	13.3	0.28	1.23	101532
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	NTLA	13.88	17.4	-37.5	-3.58
2026-03-10	NTLA	13.47	17.4	-0.8	-3.56
2026-03-11	NTLA	13.01	17.4	1.9	-3.56
2026-03-12	NTLA	12.86	17.4	-11.1	-3.56
2026-03-13	NTLA	12.76	17.4	-14.1	-3.56
2026-03-17	NTLA	13.50	17.4	-23.4	-3.56
2026-03-18	NTLA	13.21	17.4	-6.4	-3.56
2026-03-19	NTLA	13.15	17.4	-16.0	-3.56
2026-03-20	NTLA	12.86	17.4	-5.1	-3.56
2026-03-23	NTLA	13.10	17.4	-30.0	-3.56
2026-03-24	NTLA	12.80	17.4	-4.0	-3.56
2026-03-25	NTLA	13.27	17.4	-39.8	-3.56
2026-03-26	NTLA	13.24	17.4	-17.5	-3.56
2026-03-27	NTLA	12.37	17.4	20.7	-3.56
2026-03-30	NTLA	11.66	17.4	17.1	-3.56
2026-03-31	NTLA	12.81	17.4	-79.3	-3.56
2026-04-01	NTLA	13.27	17.4	-39.3	-3.56
2026-04-02	NTLA	13.12	17.4	-12.1	-3.56
2026-04-06	NTLA	13.30	17.4	-26.5	-3.56
2026-04-07	NTLA	13.56	17.4	-30.5	-3.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	NTLA	-0.42	1.53	40.38
2026-03-10	NTLA	-0.42	1.53	40.38
2026-03-11	NTLA	-0.42	1.53	39.53
2026-03-12	NTLA	-0.42	1.53	39.53
2026-03-13	NTLA	-0.42	1.53	39.53
2026-03-17	NTLA	-0.42	1.54	39.53
2026-03-18	NTLA	-0.42	1.54	39.53
2026-03-19	NTLA	-0.42	1.54	39.53
2026-03-20	NTLA	-0.42	1.54	39.53
2026-03-23	NTLA	-0.42	1.54	39.53
2026-03-24	NTLA	-0.42	1.54	39.53
2026-03-25	NTLA	-0.42	1.54	35.19
2026-03-26	NTLA	-0.42	1.54	35.19
2026-03-27	NTLA	-0.42	1.54	35.19
2026-03-30	NTLA	-0.42	1.54	35.19
2026-03-31	NTLA	-0.42	1.54	35.19
2026-04-01	NTLA	-0.42	1.54	35.19
2026-04-02	NTLA	-0.42	1.54	35.19
2026-04-06	NTLA	-0.39	0.03	35.19
2026-04-07	NTLA	-0.39	0.03	35.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.83

Avg. EPS Est. Current Quarter

-0.91

Avg. EPS Est. Next Quarter

-0.9

Insider Transactions

-0.39

Institutional Transactions

0.03

Beta

2.04

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.3

Max Drawdown 5-Year %

-96.4

Target Price

25.2

P/E

Forward P/E

PEG

P/S

23.65

P/B

2.35

P/Free Cash Flow

EPS

-3.83

Average EPS Est. Cur. Y

-3.56

EPS Next Y. (Est.)

-2.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-609.85

Relative Volume

0.48

Return on Equity vs Sector %

-88.9

Return on Equity vs Industry %

-72.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

-30.5

◆ NTLA Healthcare

$13.55

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

13/25

Volume

8/15

Valuation

12/20

TP/AR

3/10

Options

0/10

RSI

54.5

Range 1M

68.8%

Sup Dist

3.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

19/30

Estimates

5/20

Inst/Vol

6/15

Options

0/10

EPS Yr

EPS NY

44.7%

52W%

33.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +86% upside

Quality

6/30

Valuation

16/30

Growth

16/25

Stability

9/10

LT Trend

3/5

Upside

+86%

Quality

Intellia Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 377

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA

Latest News

—

Caricamento notizie per NTLA…

stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today

news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance

stock history NTLA – Intellia Therapeutics, Inc. invest stock market

stock prices NTLA premarket after hours

ticker NTLA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NTLA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y